UIC-2012-132: A new approach to treating CNS, inflammatory, autoimmune and oncology diseases; Potent and selective inhibitors of Histone Deacetylase 6 (HDAC6)

HDAC6 has unique features and has a great role in cancer therapy. There are numerous diseases that are related to dysregulated HDAC enzymatic function. Many of these diseases impact the immune system or are related to carcinogenic cellular pathways controlled by HDAC function. There are numerous clinical candidates that are designed to inhibit HDAC activity. The majority of these compounds are nonselective and lack of ability to target specific HDAC enzymes and can contribute to unwanted side effects. The investigators at UIC have developed several HDAC6 selective inhibitors that can be developed as promising therapies for autoimmune, oncology and inflammation indications. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More